Athenex’s clinical pipeline includes small molecule, biologic, and cell therapies for the treatment of cancer.

ModalityCandidateTarget / CombinationIndicationPre-clinicalPhase IPhase II/PivotalStage
Cell Therapy Platform
Autologous
CAR-NKT
KUR-501GD2R/R High Risk
Neuroblastoma
GINAKIT2
Phase I — GINAKIT2
Allogeneic
CAR-NKT
KUR-502CD19R/R Lymphoma
and Leukemia
ANCHOR
Phase I
Allogeneic
CAR-NKT
KUR-503GPC3Advanced HCC
Pre-clinical
Allogeneic
TCR-NKT
p53, KRAS,
EGFR driver mutations
Genetically Driven
Epithelial Cancers
Pre-clinical
Orascovery Platform
Oral
Chemotherapy
Oral paclitaxel
+ encequidar
dostarlimabNeoadjuvant
Breast Cancer
I-SPY 2
Phase II — I-SPY 2
Oral
Chemotherapy
Oral paclitaxel
+ encequidar
pembrolizumabSolid Tumors
KX-ORAX-011
Phase I — KX-ORAX-011

For more information about our trials, please visit clinicaltrials.gov.